000179024 001__ 179024
000179024 005__ 20240229145529.0
000179024 0247_ $$2doi$$a10.1002/alz.12614
000179024 0247_ $$2pmid$$apmid:35234335
000179024 0247_ $$2ISSN$$a1552-5260
000179024 0247_ $$2ISSN$$a1552-5279
000179024 0247_ $$2altmetric$$aaltmetric:123940922
000179024 037__ $$aDKFZ-2022-00406
000179024 041__ $$aEnglish
000179024 082__ $$a610
000179024 1001_ $$0P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aStocker, Hannah$$b0$$eFirst author$$udkfz
000179024 245__ $$aAssociation of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.
000179024 260__ $$aHoboken, NJ$$bWiley$$c2023
000179024 3367_ $$2DRIVER$$aarticle
000179024 3367_ $$2DataCite$$aOutput Types/Journal article
000179024 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674658409_22160
000179024 3367_ $$2BibTeX$$aARTICLE
000179024 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179024 3367_ $$00$$2EndNote$$aJournal Article
000179024 500__ $$a#EA:C070#LA:C070# / 2023 Jan;19(1):25-35
000179024 520__ $$aBlood biomarkers for Alzheimer's disease (AD) are the future of AD risk assessment. The aim of this study was to determine the association between plasma-measured phosphorylated tau (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) levels and risk of clinical AD incidence with consideration to the impact of cardiovascular health.Within a community-based cohort, biomarker levels were measured at baseline using single molecule array technology in 768 participants (aged 50-75) followed over 17 years. Associations among biomarkers and AD, vascular dementia, and mixed dementia incidence were assessed.GFAP was associated with clinical AD incidence even more than a decade before diagnosis (9-17 years), while p-tau181 and NfL were associated with more intermediate AD risk (within 9 years). Significant interaction was detected between cardiovascular health and p-tau181/NfL.GFAP may be an early AD biomarker increasing before p-tau181 and NfL and the effect modifying role of cardiovascular health should be considered in biomarker risk stratification.
000179024 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179024 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179024 650_7 $$2Other$$aAlzheimer's disease
000179024 650_7 $$2Other$$ablood biomarkers
000179024 650_7 $$2Other$$acardiovascular risk
000179024 650_7 $$2Other$$arisk stratification
000179024 650_7 $$2Other$$avascular dementia
000179024 7001_ $$aBeyer, Léon$$b1
000179024 7001_ $$aPerna, Laura$$b2
000179024 7001_ $$aRujescu, Dan$$b3
000179024 7001_ $$aHolleczek, Bernd$$b4
000179024 7001_ $$aBeyreuther, Konrad$$b5
000179024 7001_ $$aStockmann, Julia$$b6
000179024 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b7$$udkfz
000179024 7001_ $$aGerwert, Klaus$$b8
000179024 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$eLast author$$udkfz
000179024 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.12614$$gp. alz.12614$$n1$$p23$$tAlzheimer's and dementia$$v19$$x1552-5260$$y2023
000179024 909CO $$ooai:inrepo02.dkfz.de:179024$$pVDB
000179024 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179024 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000179024 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000179024 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179024 9141_ $$y2022
000179024 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-01-28$$wger
000179024 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000179024 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000179024 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000179024 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000179024 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000179024 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000179024 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000179024 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000179024 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000179024 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000179024 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000179024 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000179024 980__ $$ajournal
000179024 980__ $$aVDB
000179024 980__ $$aI:(DE-He78)C070-20160331
000179024 980__ $$aUNRESTRICTED